4.5 Editorial Material

Importance of Quantifying Drug-Target Engagement in Cells

Journal

ACS MEDICINAL CHEMISTRY LETTERS
Volume 11, Issue 4, Pages 403-406

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.9b00570

Keywords

-

Funding

  1. Engineering and Physical Sciences Research Council (EPSRC)
  2. Medical Research Council (MRC) [EP/L016044/1, 1097737]
  3. AbbVie
  4. Bayer Pharma AG
  5. Boehringer Ingelheim
  6. Canada Foundation for Innovation
  7. Eshelman Institute for Innovation
  8. Genome Canada
  9. Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant] [115766]
  10. Janssen
  11. Merck KGaA Darmstadt Germany
  12. MSD
  13. Novartis Pharma AG
  14. Ontario Ministry of Economic Development and Innovation
  15. Pfizer
  16. Sao Paulo Research Foundation-FAPESP
  17. Takeda
  18. Wellcome [106169/ZZ14/Z]

Ask authors/readers for more resources

Measuring and quantifying the binding of a drug to a protein target inside living cells and thereby correlating biochemical or biophysical activity with target engagement in cells or tissue represents a key step in target validation and drug development. A prototypic target engagement assay should allow for unbiased determination of small molecule-protein interactions in order to confirm cellular mechanism-of-action (MoA) while avoiding major artificial perturbations of cellular homeostasis and integrity. Recently, several new additions to the chemical biology toolbox have expanded our ability to study drug action in intact cells and enabled surveying of intracellular residence time and binding kinetics, which are particularly important for potent receptor ligands and therapeutic moieties with limited therapeutic index.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available